

**Blue Cross Blue Shield of Vermont and The Vermont Health Plan
Prior Approval Form
Aranesp® (darbepoetin alpha)
BCBSVT and TVHP Fax # (888)-255-1006**

PLEASE COMPLETE THE FOLLOWING SECTIONS:

Date of Request _____ Patient Name: _____
 Member ID#: _____ Date of Birth: _____
 Provider Name: _____ Provider Phone: _____
 Provider Fax: _____ PCP Name: _____

INDICATIONS FOR USE

	<u>YES</u>	<u>NO</u>
1. Anemic patients with chronic renal failure. (<i>Aranesp</i> ®) <ul style="list-style-type: none"> • Transferrin saturation > 20% • Ferritin > 100ng/mL • If a non-dialysis patient hematocrit <30% • Is patients HgB greater than or equal to 12 g/dL 	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
2. Anemia in non-myeloid cancer patients on chemotherapy. (<i>Aranesp</i> ®) <ul style="list-style-type: none"> • Cancer is a non-myeloid malignancy • Chemotherapy is indicated for > 2 months 	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
3. Does patient have Hypersensitivity to mammalian cell derived products or to human albumin?	<input type="checkbox"/>	<input type="checkbox"/>
4. Does patient have Uncontrolled Hypertension?	<input type="checkbox"/>	<input type="checkbox"/>
5. Will Prescription be dispensed at (circle one): Provider Office Network Pharmacy		

Initial approval will be for 4 months at which time patient should be evaluated for response. DISPENSE in no greater than 30 day supplies.

Dose: _____ Frequency: _____ HgB: _____ Hct: _____

Transferrin Saturation _____ Ferritin _____

PRESCRIBER SIGNATURE _____ DATE _____

By signing above, the prescriber confirms all information provided is accurate and verifiable via member records.